
|Articles|January 15, 2021
Supplements and Featured Publications
- The Effect of Intravenous Taxane-Related Toxicities on Metastatic Breast Cancer Disease Treatment and Healthcare Costs
The Effect of Intravenous Taxane-Related Toxicities on Metastatic Breast Cancer Disease Treatment and Healthcare Costs
Advertisement
This publication was supported by Athenex Oncology.
This AJMC® Clinical Brief explores the effect that taxane-related toxicities have on the treatment of metastatic breast cancer and healthcare costs, including the economic and clinical burdens. This publication also includes thought leader perspectives from the Medical Director of Managed Care at OneOncology, John Fox, MD, MHA.
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
In CLL, Fixed-Duration Venetoclax Combos Are Equal to Continuous Ibrutinib in Head-to-Head Comparison
2
Fixed-Duration Epcoritamab Plus Chemotherapy Yields Response, Remissions in DLBCL
3
Making the Genetic Models Match the Ancestry of Patient Populations
4
Once-Monthly Maridebart Cafraglutide Shows Up to 16% Weight Loss
5














































